The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma.

Szczegóły
Abstrakt

Tytuł:: The impact of patient preference in the treatment algorithm for recurrent/metastatic head and neck squamous cell carcinoma.
Autorzy:: Salvestrini V; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Becherini C; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Desideri I; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Caprara L; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Mariotti M; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Banini M; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Pierossi N; Otolaryngology Head & Neck department Meyer Hospital, Florence, Italy.
Scotti V; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Livi L; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy.
Bonomo P; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, University of Florence, largo Brambilla 3, 50134, Florence, Italy. .
Źródło:: La Radiologia medica [Radiol Med] 2022 Aug; Vol. 127 (8), pp. 866-871. Date of Electronic Publication: 2022 Jun 25.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Milan : Springer Milan
Original Publication: Torino [etc.] Minerva medica.
MeSH Terms:: Head and Neck Neoplasms*/drug therapy
Patient Preference*
Algorithms ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Quality of Life ; Squamous Cell Carcinoma of Head and Neck/drug therapy
References:: J Clin Oncol. 2015 Oct 10;33(29):3322-7. (PMID: 26351336)
Head Neck. 2017 Feb;39(2):215-218. (PMID: 27507712)
Cancers (Basel). 2020 Nov 30;12(12):. (PMID: 33266011)
Radiol Med. 2017 Dec;122(12):952-959. (PMID: 28849308)
N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101)
Acta Otorhinolaryngol Ital. 2021 Feb;41(1):18-23. (PMID: 33746218)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
Clin Oncol (R Coll Radiol). 2011 Oct;23(8):518-24. (PMID: 21550217)
Laryngoscope. 2010 Jul;120(7):1336-41. (PMID: 20564718)
Eur J Cancer. 2000 May;36(8):1032-7. (PMID: 10885608)
J Clin Oncol. 2000 Feb;18(4):877-84. (PMID: 10673531)
Radiol Med. 2015 Dec;120(12):1153-69. (PMID: 25981380)
J Clin Oncol. 1995 Sep;13(9):2369-78. (PMID: 7666096)
Ann Otol Rhinol Laryngol. 1997 Aug;106(8):693-9. (PMID: 9270436)
Oral Oncol. 2016 Jan;52:18-23. (PMID: 26578389)
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1643-1650. (PMID: 27844223)
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683. (PMID: 31189965)
Crit Rev Oncol Hematol. 2021 Jan;157:103200. (PMID: 33321152)
Curr Opin Oncol. 2017 May;29(3):159-165. (PMID: 28282344)
Cancer. 2019 Apr 15;125(8):1281-1289. (PMID: 30645761)
Oral Oncol. 2016 Nov;62:44-53. (PMID: 27865371)
Head Neck. 2018 Feb;40(2):312-323. (PMID: 28963819)
Oral Oncol. 2012 Oct;48(10):923-937. (PMID: 22525604)
Ann Oncol. 2010 Oct;21(10):1967-1973. (PMID: 20335368)
Lancet Oncol. 2015 May;16(5):583-94. (PMID: 25892145)
Oral Oncol. 2012 Aug;48(8):723-9. (PMID: 22414289)
Ann Palliat Med. 2021 Apr;10(4):4868-4877. (PMID: 33832317)
JAMA Oncol. 2017 Nov 01;3(11):1487-1494. (PMID: 28542679)
Head Neck. 2001 Mar;23(3):201-13. (PMID: 11428450)
Front Oncol. 2017 May 09;7:72. (PMID: 28536670)
Head Neck. 1998 Oct;20(7):600-8. (PMID: 9744459)
Radiol Med. 2020 Dec;125(12):1301-1310. (PMID: 32415474)
Head Neck. 2020 Jan;42(1):33-42. (PMID: 31584746)
N Engl J Med. 1981 Oct 22;305(17):982-7. (PMID: 7278922)
Head Neck. 1999 Sep;21(6):538-46. (PMID: 10449670)
Head Neck. 1993 Nov-Dec;15(6):485-96. (PMID: 8253555)
J Oncol Pract. 2017 Apr;13(4):e319-e328. (PMID: 28267393)
Eur Arch Otorhinolaryngol. 2013 Mar;270(3):1067-74. (PMID: 22743645)
Ann Oncol. 2020 Nov;31(11):1462-1475. (PMID: 33239190)
Laryngoscope. 2018 Mar;128(3):664-669. (PMID: 28865100)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Eur Arch Otorhinolaryngol. 2013 Nov;270(12):3133-42. (PMID: 23543319)
Contributed Indexing:: Keywords: Immunotherapy; Patient’s preference; Pembrolizumab; Quality of life; Recurrent or metastatic HNSCC
Local Abstract: [Publisher, Italian] L'avvento degli inibitori del checkpoint immunitario per il carcinoma squamocellulare ricorrente/metastatico del distretto testa e collo (RM-HNSCC) ha rivoluzionato l'approccio standard di cura nel trattamento di prima linea di questa malattia. L'eterogeneità di presentazione del RM-HNSCC e le tossicità correlate al trattamento possono essere associate a una compliance non ottimale del paziente alle cure oncologiche. Per tale ragione, qualità della vita e benessere del paziente sono aspetti cruciali da considerare per definire la migliore scelta di trattamento. Lo scopo del nostro lavoro è presentare una panoramica sul tema della preferenza del paziente rispetto al trattamento e delle sue conseguenze sulla qualità della vita in ambito di malattia recidivante/metastatica. Secondo la letteratura infatti, esiste un'esigenza concreta su come valutare l'atteggiamento del paziente rispetto alla scelta del trattamento. In considerazione della disponibilità di diverse strategie terapeutiche nella gestione di prima linea di RM-HNSCC, si dovrebbe dunque porre maggiore enfasi sull'integrazione delle preferenze del paziente nell’individuazione dell’iter terapeutico.
Entry Date(s):: Date Created: 20220625 Date Completed: 20220805 Latest Revision: 20220806
Update Code:: 20240105
PubMed Central ID:: PMC9349154
DOI:: 10.1007/s11547-022-01509-1
PMID:: 35752659
: Czasopismo naukowe

Full Text Finder

The advent of immune checkpoint inhibitors for recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) has revolutionized the standard of care approach in first-line treatment. The heterogeneity of disease presentation and treatment-related toxicities can be associated with suboptimal patient compliance to oncologic care. Hence, prioritizing quality of life and well-being are crucial aspects to be considered in tailoring the best treatment choice. The aim of our work is to present a short report on the topic of the patient's preference in regard to treatment and its consequences on quality of life in the recurrent/metastatic setting. According to the literature, there's an unmet need on how to assess patient attitude in respect to the choice of treatment. In view of the availability of different therapeutic strategies in first-line management of RM-HNSCC, increasing emphasis should be put on integrating patient preferences into the medical decision-making.
(© 2022. The Author(s).)

Informacja